Baker Bros. Advisors LP Bei Gene, Ltd. Transaction History

Baker Bros. Advisors LP

$9.02 Billion
Q4 2024

A detailed history of Baker Bros. Advisors LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 9,531,880 shares of BGNE stock, worth $2.16 Billion. This represents 19.52% of its overall portfolio holdings.

Number of Shares

9,531,880

Previous 10,568,897 9.81%

Holding current value

$2.16 Billion

Previous $2.37 Billion 25.8%

% of portfolio

19.52%

Previous 25.41%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$174.72 - $246.04 $181 Million - $255 Million	-1,037,017 Reduced 9.81%	9,531,880 $1.76 Billion
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $175 Million - $222 Million	-1,100,000 Reduced 9.43%	10,568,897 $1.91 Billion
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $361 Million - $517 Million	-1,632,700 Reduced 12.27%	11,668,897 $3.02 Billion
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $288 Million - $437 Million	1,524,312 Added 12.94%	13,301,597 $3.81 Billion
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $20.8 Million - $26.8 Million	-182,539 Reduced 1.53%	11,777,285 $1.46 Billion
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $935 Million - $1.33 Billion	6,130,395 Added 105.16%	11,959,824 $1.84 Billion
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $193 Million - $351 Million	1,980,198 Added 51.44%	5,829,429 $979 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $3.92 Million - $5.64 Million	-49,200 Reduced 1.26%	3,849,231 $376 Million
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $258 Million - $403 Million	3,898,431	3,898,431 $403 Million

Others Institutions Holding BGNE

# of Institutions

254

Shares Held

42.4M

Call Options Held

135K

Put Options Held

111K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Bei Gene, Ltd. Transaction History